Future studies can address whether impaired ephrin-B1 expression in astrocytes is associated with demyelinating diseases such as MS and explore whether astrocytic ephrin-B1 may be useful as a therapeutic target to promote remyelination and oligodendrocyte survival in demyelinating diseases. This evidence concerns the gene EFNB1 and myeloid sarcoma.